Immunotherapy is a mainstay of lung cancer treatment, and its side effects are different from chemotherapy's. Here are five to know, what they feel like and how care teams treat them.
|Articles|September 24, 2015
Lecia V. Sequist Provides an Overview of T790M Mutations in NSCLC
Author(s)Lecia V. Sequist
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene. T790M is the primary cause of treatment resistance in EGFR-positive patients with non-small cell lung cancer (NSCLC).
Advertisement
Related to this article
Brad Dugai and Russ Reed discuss symptom relief, skin-related side effects and challenges accessing Rasonque, a treatment for pancreatic cancer.
Patients with PD-L1-negative non-small cell lung cancer experienced longer progression-free survival with sac-TMT plus Keytruda compared with chemotherapy plus Keytruda in a phase 3 trial.
A nurse practitioner discusses how an app provides information on cancer treatments, potential side effects and preparing for medical appointments.
Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
For Lung Cancer Awareness Month, answers to common patient questions about biomarker testing in non-small cell lung cancer: which gene changes doctors look for, blood vs. tissue tests, insurance and retesting.
A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
Advertisement
Advertisement
Trending on CURE
1
Why a Patient With Pancreatic Cancer Moved From Chemotherapy to Rasonque
2
Sac-TMT Plus Keytruda Improves Outcomes in PD-L1-Negative Lung Cancer
3
Rasonque for Pancreatic Cancer: Patients Discuss Benefits, Risks and Access
4
After Breast Cancer, Thanksgiving Is No Longer Just One Day
5